Core Viewpoint - 康诺亚-B's stock rose over 3% following the announcement of successful Phase I clinical trial results for its novel long-acting TSLP x IL-13 dual inhibitor CM512, indicating strong potential in treating moderate to severe atopic dermatitis [1] Group 1: Clinical Research and Development - The Phase I clinical study for CM512 achieved all research endpoints, demonstrating rapid disease control and deep, sustained relief in patients with moderate to severe atopic dermatitis [1] - CM512 has a long half-life of 70 days and shows good safety profiles, suggesting its potential as a best-in-class treatment for adult patients with moderate to severe atopic dermatitis [1] Group 2: Mechanism of Action - CM512 is the world's first IgG-like long-acting TSLP x IL-13 dual inhibitor, targeting both TSLP and IL-13 to effectively reduce Th2 cell differentiation and the release of cytokines like IL-13 [1] - The drug aims to inhibit the initiation of inflammatory cascade responses early, directly addressing the pathological symptoms driven by IL-13, thus providing a more effective treatment for type 2 inflammation-related diseases [1] Group 3: Future Development Plans - 康诺亚 is rapidly advancing CM512 into Phase II clinical studies for various indications, including atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria [1]
康诺亚-B逆市涨超3% TSLP x IL-13双抗CM512特应性皮炎I期临床达成全部研究终点